Celgene’s Chief Executive Officer Mark Alles notes that millions of patients continue to live because of new medicines, and treatments that provide the greatest health impact for seriously ill patients should have the lowest cost-sharing requirements. Patients must also be protected from health insurance company practices that delay or deny needed care, such as adverse tiering and step therapy. Read more here.
Last Updated on May 13, 2020 by Aimed Alliance
